Whole body and intracranial efficacy of ceritinib in patients (pts) with crizotinib (CRZ) pretreated, ALK-rearranged (ALK plus ) non-small cell lung cancer (NSCLC) and baseline brain metastases (BM): Results from ASCEND-1 and ASCEND-2 trials

被引：21

作者：

Felip, E. ^{[1
]}

Crino, L. ^{[2
]}

Kim, D. -W. ^{[3
]}

Spigel, D. R. ^{[4
]}

Nishio, M. ^{[5
]}

Mok, T. ^{[6
]}

Scagliotti, G. ^{[7
]}

Cesic, D. ^{[8
]}

Sutradhar, S. ^{[9
]}

Shaw, A. T. ^{[10
]}

机构：

[1] Vail dHebron Univ Hosp, Inst Oncol, Med Oncol Serv, Barcelona, Spain

[2] Osped S Maria Misericordia, Oncol Med, Perugia, Italy

[3] Seoul Natl Univ Hosp, Dept Internal Med, Seoul, South Korea

[4] Sarah Cannon Res Inst, Med Oncol, Nashville, TN USA

[5] JFCR, Canc Inst Hosp, Thorac Med Oncol, Tokyo, Japan

[6] Chinese Univ Hong Kong, Prince Wales Hosp, Dept Clin Oncol, Hong Kong, Hong Kong, Peoples R China

[7] Univ Turino, Oncol, Turin, Italy

[8] Novartis Pharmaceut, GMA Oncol, E Hanover, NJ USA

[9] Novartis Pharmaceut, GMA Biostat, E Hanover, NJ USA

[10] Massachusetts Gen Hosp, Ctr Canc, Boston, MA USA

来源：

关键词：

D O I：

10.1016/S1556-0864(16)30251-9

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

141PD

引用

页码：S118 / S119

页数：2